The low EOMES/TBX21 molecular phenotype in multiple sclerosis reflects CD56+ cell dysregulation and is affected by immunomodulatory therapies

F.C. Mckay, P.N. Gatt, N. Fewings, G.P. Parnell, S.D. Schibeci, M.A.I. Basuki, J.E. Powell, A. Goldinger, Marzena Pedrini, Allan Kermode, T. Burke, S. Vucic, G.J. Stewart, D.R. Booth

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

© 2016 Published by Elsevier Inc. Multiple Sclerosis (MS) is an autoimmune disease treated by therapies targeting peripheral blood cells. We previously identified that expression of two MS-risk genes, the transcription factors EOMES and TBX21 (ET), was low in blood from MS and stable over time. Here we replicated the low ET expression in a new MS cohort (p
Original languageEnglish
Pages (from-to)96-107
Number of pages12
JournalClinical Immunology
Volume163
Early online date4 Jan 2016
DOIs
Publication statusPublished - Feb 2016

Fingerprint Dive into the research topics of 'The low EOMES/TBX21 molecular phenotype in multiple sclerosis reflects CD56+ cell dysregulation and is affected by immunomodulatory therapies'. Together they form a unique fingerprint.

  • Cite this

    Mckay, F. C., Gatt, P. N., Fewings, N., Parnell, G. P., Schibeci, S. D., Basuki, M. A. I., Powell, J. E., Goldinger, A., Pedrini, M., Kermode, A., Burke, T., Vucic, S., Stewart, G. J., & Booth, D. R. (2016). The low EOMES/TBX21 molecular phenotype in multiple sclerosis reflects CD56+ cell dysregulation and is affected by immunomodulatory therapies. Clinical Immunology, 163, 96-107. https://doi.org/10.1016/j.clim.2015.12.015